Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3027 - Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa


09 Oct 2016


Poster display


Noel Clarke


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


N.W. Clarke1, M. De Santis2, A.J. Costello3, Y. Chang4, T. Pickles5, A.C. Pompeo6, S. Bazarbashi7, G.P. Haas8, M.R. Cooperberg9

Author affiliations

  • 1 Urology, The Christie Hospital, M204BX - Manchester/GB
  • 2 Cancer Research Centre, University of Warwick, Coventry/GB
  • 3 Oncology, The Royal Melbourne Hospital, Melbourne/AU
  • 4 Division Of General Urology, Taipei Veterans General Hospital, Taipei/TW
  • 5 Developmental Radiotherapy And Radiotherapeutics, University of British Columbia, Vancouver/CA
  • 6 Urology, FM-ABC, Sao Paulo/BR
  • 7 Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh/SA
  • 8 Astellas Pharma Global Development, Astellas Pharma Inc., Northbrook/US
  • 9 Urologic Surgery And Oncology, University of California, San Francisco/US


Abstract 3027


ASPIRE-PCa is an observational study that aims to describe the pattern of care for men with late-stage prostate cancer (PC). 1200 patients (pts) from the Americas, Europe, Asia, and the Middle East/North Africa are targeted for enrolment. We present updated data from December 2015.


Men with prostate adenocarcinoma enrol at the diagnosis of: biochemical failure after curative-intent therapy with a prostate-specific antigen (PSA) doubling time of ≤1 year; castration-resistant PC (CRPC); or metastatic PC (mPC) at initial presentation. Initial treatment decision and planned follow-up data were collected.


507 pts have enrolled from 72 sites in 21 countries: Americas, n = 53; Europe, n = 172; Asia, n = 271; and the Middle East/North Africa, n = 11. Biochemical failure, n = 90 (18%); CRPC, n = 181 (36%); mPC, n = 235 (46%); and missing, n = 1 (100%, as >1 option/pt). Enzalutamide was less frequently chosen (n = 7; 3%). The most favoured follow-up was PSA testing every 3 months. Updated regional differences will be presented.

New treatment,a n (%) 277 (109%)
Androgen-deprivation therapy 244 (88%)
Chemotherapy, immunotherapy, targeted therapy 46 (17%)
Salvage radiotherapy 11 (4%)
Androgen-deprivation therapy, n (%) 223 (∼100%)
GnRH agonist and anti-androgen 90 (40%)
GnRH agonist alone 67 (30%)
Anti-androgen alone 26 (12%)
2nd-generation androgen-directed therapy 25 (11%)
Treatment missing 7 (3%)
GnRH antagonist alone 4 (2%)
GnRH antagonist and anti-androgen 2 (


The updated results from ASPIRE-PCa indicate that most late-stage PC pts receive ADT as a GnRH agonist/aa combination; disease status drives treatment choice; and the most common follow-up is PSA testing every 3 months. Leuprolide and bicalutamide are the most common initial interventions.

Clinical trial identification

NCT02066961 - First received: February 18, 2014; Last updated: February 4, 2016

Legal entity responsible for the study

Astellas Pharma, Inc.


Astellas Pharma, Inc.


N.W. Clarke: Advisory boards for Astellas, AstraZeneca, Bayer, Ferring, Janssen, Ipsen, Sanofi Aventis and Pfizer.

M. De Santis, S. Bazarbashi: The author discloses that they are a member of the ASPIRE steering comitee and have received a research grant from Astellas Pharma Inc.

T. Pickles: The author discloses that they have a substantive relationship with Sanofi Aventis and Oncurra.

G.P. Haas: The author discloses that they are the senior medical director at Astellas Pharma Inc.

M.R. Cooperberg: Employee of Astellas Pharma, Inc.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.